Codexis, Inc.
A maker of custom-engineered enzymes, Codexis grows proteins in the lab to speed up drug-making and other industrial processes, with uses ranging from pharmaceuticals (including a key ingredient in the cholesterol drug Lipitor) to food and RNA therapies. Born in 2002 as a spin-off from biotech firm Maxygen, the company built its craft on "directed evolution" — mimicking natural selection in a dish to breed better enzymes through its CodeEvolver platform. Its name blends "code" and "exis" (evolution), a nod to the very process that powers it.
Bought 5.26M · Sold 2.66M
Granted 662.1K · Sold 900.9K
Granted 694.9K · Bought 58.5K · Sold 55.1K
Granted 237.9K · Sold 10.1K
Granted 96.0K · Sold 40.0K
Granted 117.0K
Granted 185.2K · Bought 9.0K · Sold 16.9K
Granted 164.1K · Bought 11.7K
Granted 143.6K
Granted 117.0K · Sold 24.0K
Granted 137.1K
Granted 137.6K · Bought 11.8K · Sold 15.7K
Sold 13.0K
Granted 117.0K
Granted 112.2K
Granted 85.1K
Granted 88.8K · Sold 4.0K
Granted 76.9K · Sold 10.1K
Granted 45.9K
Granted 11.3K · Sold 16.0K
Granted 20.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Opaleye Management Inc.10% owner · 59 transactions | — | 10.13M | — | 5.26M | 2.66M |
| Nicols John JDirector · 46 transactions | -25.9% | 784.0Kas of Apr 2023 | 662.1K | — | 900.9K |
| Dilly Stephen GeorgeDirector · 9 transactions | +3102.7% | 727.1K | 694.9K | 58.5K | 55.1K |
| Moore AlisonPresident and CEO, Director · 8 transactions | +1003.5% | 250.5K | 237.9K | — | 10.1K |
| Dorgan Byron LDirector · 7 transactions | +33.4% | 223.6Kas of Jun 2024 | 96.0K | — | 40.0K |
| Smith David VDirector · 7 transactions | +139% | 194.3Kas of Jun 2025 | 117.0K | — | — |
| Norrett KevinChief Operating Officer · 7 transactions | — | 177.3Kas of Feb 2025 | 185.2K | 9.0K | 16.9K |
| Ryali SriramChief Financial Officer · 3 transactions | — | 175.8Kas of Jan 2024 | 164.1K | 11.7K | — |
| Parker H StewartDirector · 4 transactions | — | 143.6Kas of Jun 2025 | 143.6K | — | — |
| Wolf Dennis PDirector · 10 transactions | +202.6% | 139.0K | 117.0K | — | 24.0K |
| Singhvi RahulDirector · 4 transactions | — | 137.1Kas of Jun 2025 | 137.1K | — | — |
| Fitzgerald Margaret NellSee Remarks · 6 transactions | — | 133.8Kas of Jan 2024 | 137.6K | 11.8K | 15.7K |
| Lutz StefanChief Scientific Officer · 3 transactions | — | 130.4K | — | — | 13.0K |
| Martinborough EstherDirector · 4 transactions | +970.1% | 129.0Kas of Jun 2025 | 117.0K | — | — |
| Collins CynthiaDirector · 2 transactions | — | 112.2Kas of Jun 2025 | 112.2K | — | — |
| Richards ChristosDirector · 2 transactions | — | 85.1Kas of Jun 2025 | 85.1K | — | — |
| De Vre RaymondDirector · 4 transactions | — | 84.8K | 88.8K | — | 4.0K |
| Erbez GeorgiaSee Remarks · 4 transactions | — | 66.8K | 76.9K | — | 10.1K |
| Aaker JenniferDirector · 2 transactions | +225.6% | 66.2Kas of Jun 2023 | 45.9K | — | — |
| Yang Patrick YDirector · 4 transactions | -8.1% | 53.8Kas of Jun 2022 | 11.3K | — | 16.0K |
| Taylor Dean Ross JrAdvisor · 5 transactions | +63.6% | 38.6Kas of Feb 2023 | 20.6K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +1.59M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.